| Not Yet Recruiting | Inectolizumab With Steroid Optimization in Newly Treated NMOSD NCT07159893 | First Affiliated Hospital of Wenzhou Medical University | N/A |
| Recruiting | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Diso NCT06398158 | University of Texas Southwestern Medical Center | — |
| Not Yet Recruiting | FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack NCT06497374 | Tianjin Medical University General Hospital | Phase 2 |
| Unknown | Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders NCT06118398 | Feng Jinzhou | — |
| Recruiting | Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD NCT05566769 | Ad scientiam | N/A |
| Completed | Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica NCT05828212 | Zhejiang University | Phase 1 |
| Active Not Recruiting | Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Sp NCT05403138 | Tianjin Medical University General Hospital | Phase 2 / Phase 3 |
| Unknown | Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder NCT05573711 | Dokuz Eylul University | — |
| Unknown | An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients NCT05356858 | Xuanwu Hospital, Beijing | Phase 2 |
| Enrolling By Invitation | Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders NCT05982925 | Icahn School of Medicine at Mount Sinai | — |
| Unknown | Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical S NCT05245344 | Neuromed IRCCS | — |
| Unknown | Lifestyle Weight Management Program: Interviews and Stakeholder Meetings. NCT05070286 | Oxford Brookes University | — |
| Completed | High Frequency Impulse Therapy for Neuropathic Pain in NMOSD NCT04614454 | Massachusetts General Hospital | Phase 2 |
| Unknown | Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorp NCT04601142 | Beijing Tongren Hospital | — |
| Completed | Safety of Therapeutic Step-down in Neuromyelitis Optica NCT05155644 | University Hospital, Strasbourg, France | — |
| Completed | In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients NCT04629274 | Imcyse SA | N/A |
| Terminated | A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica NCT04155424 | Alexion Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD NCT04201262 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Withdrawn | Autologous Transplant To End NMO Spectrum Disorder NCT03829566 | Northwestern University | Phase 2 / Phase 3 |
| Completed | PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. NCT03942952 | University of Texas Southwestern Medical Center | — |
| Withdrawn | MS and NMOSD in African-Americans NCT04131673 | Jagannadha R Avasarala | — |
| Unknown | Optic Neuritis Differential Diagnosis Study NCT03370965 | University Hospital Center of Martinique | N/A |
| Completed | Scrambler Trial for Pain in NMOSD NCT03452176 | Johns Hopkins University | N/A |
| Completed | Pediatric NMOSD Observational Study NCT03766347 | Mayo Clinic | — |
| Completed | Immunologic Biomarker Profile of Cerebrospinal Fluid NCT04202055 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders NCT03350633 | Tianjin Medical University General Hospital | Phase 2 / Phase 3 |
| Completed | A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD NCT03062579 | Fu-Dong Shi | Phase 1 / Phase 2 |
| Completed | Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses NCT02276963 | Johns Hopkins University | Phase 1 |
| Completed | Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase NCT02283671 | Sara Varea | Phase 1 |
| Terminated | A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse NCT02398994 | Guy's and St Thomas' NHS Foundation Trust | Phase 3 |
| Completed | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients NCT02003144 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Terminated | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) NCT01892345 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | Neuromyelitis Optica (NMO) & Cetirizine NCT02865018 | Icahn School of Medicine at Mount Sinai | Phase 1 / Phase 2 |
| Withdrawn | Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses NCT02087813 | Stanford University | Phase 1 |
| Completed | Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) NCT02166346 | Johns Hopkins University | Phase 2 |
| Completed | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations NCT01777412 | Johns Hopkins University | Phase 1 |
| Completed | C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation NCT01759602 | Michael Levy | Phase 1 |
| Completed | Maintenance Plasma Exchange for Neuromyelitis Optica NCT01500681 | Mayo Clinic | — |
| Active Not Recruiting | The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders NCT01623076 | University of Texas Southwestern Medical Center | — |
| Terminated | Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica NCT01339455 | University of Calgary | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Scl NCT01364246 | Shenzhen Beike Bio-Technology Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct NCT01024985 | University of Sao Paulo | — |
| Completed | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica NCT00904826 | Mayo Clinic | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders NCT02021825 | Xuanwu Hospital, Beijing | Phase 4 |
| Active Not Recruiting | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases NCT00716066 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Biobank For MS And Other Demyelinating Diseases NCT00445367 | Accelerated Cure Project for Multiple Sclerosis | — |
| Completed | Safety and Tolerability of Rituximab in Neuromyelitis Optica NCT00501748 | University of California, San Francisco | Phase 1 |
| Completed | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) NCT00304291 | State University of New York at Buffalo | Phase 4 |